Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Christy J. Wilson
Sr. Director, Pharma and Biotech Segment
Connect with Christy J. Wilson on LinkedIn
Follow Christy J. Wilson on Twitter
About the author:
Christy brings more than 20 years of global life science and healthcare industry experience to her role as Senior Director, Segment Marketing for the biopharmaceutical industry segment at Elsevier. In this capacity she is focused on understanding biopharmaceutical R&D challenges and the implications for Elsevier in terms of market led growth opportunities that will improve productivity and success for industry executives and their teams. She also plays a key role in increasing Elsevier’s share-of-voice and market share through strategic go-to-market planning and execution.
Prior to joining Elsevier, Christy held senior marketing and business development roles in Wolters Kluwer’s Pharma Solutions Business Unit where she was responsible for product management and marketing of the Adis portfolio of drug focused journals and newsletters, pipeline and clinical trials intelligence tools, and pharmacovigilance solutions. During her Wolters Kluwer tenure, Christy also worked in the group’s Healthcare Analytics business, a business that provided powerful data, applications, analytics, and consulting to help companies gain deep insight into the pharmaceutical market.
Christy resides in the greater New York City area and holds an MBA in International Business from DePaul University (Chicago) and a BS in Marketing, from Miami University (Ohio).
Posts by Christy J. Wilson
Posted on December 8th, 2018 in Pharma R&D
Although R&D competition remains as fierce as ever, many pharmaceutical companies engage in various types of cooperation and partnership ventures to help drive innovation. The goal of coopetition — when companies cooperate on certain projects while maintaining a competitive stance — is to make drug development more efficient and effective. (more…)
Posted on December 4th, 2018 in Pharma R&D
With its groundbreaking work in developing antibody-drug conjugates, antibiotics, anti-coagulants and anti-cancer therapies, LegoChem Biosciences was already doing important research before joining The Hive. (more…)
Posted on November 29th, 2018 in Pharma R&D
When is a startup no longer a startup? Small biotech companies armed with a talented crop of scientists have been springing up all across the pharma landscape for the last several years, establishing buzzing hubs of innovation. Not all of them find their research efforts successful, but many do and then go on to be acquired by larger pharmaceutical firms that have the resources to bring their ideas to fruition. (more…)
Posted on November 22nd, 2018 in Pharma R&D
Since our founding back in 2006, LegoChem Biosciences (LCB) has focused on the research and development of anti-biotic, anti-coagulant, anti-fibrosis and Antibody-Drug Conjugate (ADC) therapeutics based on our proprietary platform technology, LegoChemistry™ & Conjuall™. LCB is comprised of researchers who have varied backgrounds and R&D experiences, including the development of Factive, the first US FDA-approved drug developed in Korea. (more…)